August 14, 2025
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Screening, therapy options focus of updated primary aldosteronism guideline
SAN FRANCISCO — A new clinical practice guideline emphasized screening all patients with hypertension for primary aldosteronism. The Endocrine Society published its first update to the primary aldosteronism clinical practice guideline since 2016 in The Journal of Clinical Endocrinology & Metabolism. The guideline, which was also discussed during a symposium at ENDO 2025, focused heavily
TL;DRAI
Endocrine Society recommends universal screening for primary aldosteronism with mineralocorticoid antagonists as first-line therapy. Market expands as 3-22% prevalence but <1% current screening rate shifts hypertension care toward targeted approaches.
1,006 words~5 min read
